EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.58
+0.02 (+3.39%)
As of 9:52AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.56
Open0.55
Bid0.55 x 1200
Ask0.56 x 900
Day's Range0.55 - 0.58
52 Week Range0.29 - 1.47
Volume25,911
Avg. Volume1,376,946
Market Cap24.251M
Beta3.19
PE Ratio (TTM)N/A
EPS (TTM)-0.79
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • ACCESSWIRE9 days ago

    Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia

    LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want access to our free research report on FibroGen, Inc. (NASDAQ: FGEN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=FGEN as the Company's latest news hit the wire. On June 07, 2018, the Company announced that it has completed patient enrollment in the Phase-3 studies supporting the US new drug application (NDA) submission for Roxadustat in anemia associated with chronic kidney disease (CKD).

  • GlobeNewswire21 days ago

    EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the filing of an Investigational Device Exemption (IDE) supplement for Punctate Epitheliopathy (PE), using the Company’s Ocular Bandage Gel (OBG) product. PE represents an unmet medical need and is an opportunity for EyeGate’s OBG platform to expand to additional indications.

  • Zacks Small Cap Research22 days ago

    EYEG: 3 of 4 FDA Questions Answered, OBG-PRK Study On-Track for Q3 Start

    Through Q1 2018, EYEG collected $12.5M related to upfront payments and development milestones from the two Valeant agreements related to EGP-437 programs in anterior uveitis and post-cataract surgery. While FDA’s requests have resulted in delays in getting the IDE through the approval process, EYEG has been diligent in responding to their questions – which has been key to keeping timelines intact.

  • Want To Invest In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Here’s How It Performed Lately
    Simply Wall St.25 days ago

    Want To Invest In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Here’s How It Performed Lately

    Examining how EyeGate Pharmaceuticals Inc (NASDAQ:EYEG) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense checkRead More...

  • GlobeNewswire29 days ago

    EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that it has addressed three of the four outstanding items in a Second Amendment in response to the U.S. Food and Drug Administration’s (FDA) review of its first amendment. EyeGate has demonstrated continued progress towards achieving the Investigational Device Exemption (IDE) for a second pilot study of the Company’s Ocular Bandage Gel (OBG) product, a cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S) platform being developed for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK).

  • GlobeNewswirelast month

    EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that Steven Boyd has joined its board. Paul Chaney, EyeGate’s Chairman, said, “We are pleased to welcome Steven Boyd to the Board of EyeGate. Mr. Boyd said, “I am excited to join the Board of a company like EyeGate with two unique and proprietary platforms that I strongly believe in.

  • GlobeNewswirelast month

    EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the three-month period ended March 31, 2018, and provided an update on recent corporate and operational activities. “During the first quarter of 2018, we were able to reinforce our core platforms at EyeGate with several strategic accomplishments, as well as operational achievements that help solidify our direction moving forward,” said Stephen From, President and Chief Executive Officer of EyeGate Pharmaceuticals. “Regarding EyeGate’s clinical operations,” Mr. From continued, “Our clinical story has advanced with the submission of the investigation device exemption (IDE) amendment for the second pilot study of ocular bandage gel (EyeGate OBG), which summarized the company’s response to the original IDE.

  • Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)?
    Simply Wall St.last month

    Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)?

    EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. EyeGate Pharmaceuticals is one of United States’s small-capRead More...

  • GlobeNewswire2 months ago

    EyeGate Announces Completion of $11.25 Million Public Offering

    WALTHAM, Mass., April 17, 2018-- EyeGate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, ...

  • GlobeNewswire2 months ago

    EyeGate Announces $11.25 Million Public Offering

    WALTHAM, Mass., April 13, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the ...

  • GlobeNewswire2 months ago

    EyeGate Issued New Patent for Iontophoretic Contact Lens Technology

    WALTHAM, Mass., April 11, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the ...

  • GlobeNewswire2 months ago

    EyeGate Receives FDA Feedback on Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel

    WALTHAM, Mass., April 09, 2018-- EyeGate Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the ...

  • GlobeNewswire2 months ago

    EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis

    WALTHAM, Mass., April 06, 2018-- EyeGate Pharmaceuticals, Inc., today announced completion of patient enrollment for the pivotal Phase 3 clinical study of its EGP-437 combination product for the treatment ...

  • EyeGate Pharmaceuticals Inc (NASDAQ:EYEG): Poised For Long-Term Success?
    Simply Wall St.3 months ago

    EyeGate Pharmaceuticals Inc (NASDAQ:EYEG): Poised For Long-Term Success?

    The most recent earnings update EyeGate Pharmaceuticals Inc’s (NASDAQ:EYEG) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recentRead More...

  • Zacks Small Cap Research4 months ago

    EYEG: Cataract Surgery Phase II Topline Data: Efficacy Signal Despite Miss to Primary Endpoint

    Earlier this month EyeGate (EYEG) announced top-line results of its phase IIb study evaluating the safety and efficacy of EGP-437 in patients which underwent cataract surgery with implantation of a monofocal posterier chamber intra-ocular lens (IOL).  Primary efficacy endpoint is the proportion of subjects with an anterior chamber (AC) cell count of zero at Day 7 and the proportion of subjects with pain score of zero at Day 1.  Secondary endpoints are change in mean ACC on Day 7 and change in mean pain score on Day 1.

  • What Spooked Eyegate Pharmaceuticals Inc Investors Today
    SmarterAnalyst4 months ago

    What Spooked Eyegate Pharmaceuticals Inc Investors Today

    The stock's double-digit nosedive was sparked by disappointing top-line results from a phase 2b trial of the company's EGP-437 combination product for pain and inflammation in patients having undergone cataract surgery. Eyegate reported that the co-primary endpoints of proportion of subjects with an anterior chamber cell (ACC) count of zero at day 7 and the proportion of subjects with a pain score of zero at day 1 did not show statistical significance. “The efficacy results for the absence of inflammatory cells in the EGP-437 treatment group met our expectations, but the vehicle group response was better than anticipated.

  • Should You Worry About Eyegate Pharmaceuticals Inc’s (NASDAQ:EYEG) CEO Pay Check?
    Simply Wall St.5 months ago

    Should You Worry About Eyegate Pharmaceuticals Inc’s (NASDAQ:EYEG) CEO Pay Check?

    Stephen From is the CEO of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG), which has recently grown to a market capitalization of $20.65M. Recognizing whether CEO incentives are aligned with shareholders is aRead More...

  • With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry?
    Simply Wall St.6 months ago

    With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry?

    Understanding how Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense checkRead More...

  • Capital Cube6 months ago

    ETFs with exposure to EyeGate Pharmaceuticals, Inc. : December 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to EyeGate Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to EYEG-US. Comparing the performance and risk of EyeGate Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)